menu
    • menu

    Company profile for RemeGen

    NEW Drugs in Dev: 16
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At RemeGen, Ltd., a leading biotech innovator in China, we believe biologics are the future of medicine—and we’re ready to take our therapeutic innovations to the global stage. We’re aligning our investments in scientific research, manufacturing and commercialization to change the way cancer, autoimmune and eye diseases are treated.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    RemeGenChina Flag
    Country
    Country
    China
    Address
    Address
    58 Middle Beijing Road, Yantai Economic and Technological Development Zone, Ya...
    Telephone
    Telephone
    (86) 535-6113513
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://remegen.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Abbvie Seeks Oncology Pipeline Respect Post Remegen Acquisition
    Abbvie Seeks Oncology Pipeline Respect Post Remegen Acquisition

    14 Jan 2026

    // BIOSPACE

    https://www.biospace.com/business/jpm26-abbvie-seeks-respect-for-oncology-pipeline-following-remegen-buy

    BIOSPACE
    14 Jan 2026
    Share Share
    AbbVie Pens $5.6B Pact with RemeGen to join PD-1xVEGF race
    AbbVie Pens $5.6B Pact with RemeGen to join PD-1xVEGF race

    12 Jan 2026

    // PRESS RELEASE

    https://news.abbvie.com/2026-01-12-AbbVie-and-RemeGen-Announce-Exclusive-Licensing-Agreement-to-Develop-A-Novel-Bispecific-Antibody-for-Advanced-Solid-Tumors

    PRESS RELEASE
    12 Jan 2026
    Share Share
    Telitacicept Shows Long-Term Efficacy In 48-Week China Ph 3 Data
    Telitacicept Shows Long-Term Efficacy In 48-Week China Ph 3 Data

    29 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/29/3176649/0/en/Telitacicept-Demonstrates-Sustained-Efficacy-and-Favorable-Safety-Profile-in-48-Week-China-Phase-3-Open-Label-Extension-Generalized-Myasthenia-Gravis-Data.html

    GLOBENEWSWIRE
    29 Oct 2025
    Share Share
    Vor Bio to Host Webcast on China Ph3 Telitacicept Sjögren’s Data
    Vor Bio to Host Webcast on China Ph3 Telitacicept Sjögren’s Data

    22 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/22/3171527/0/en/Vor-Bio-to-Host-Webcast-on-Late-Breaking-China-Phase-3-Telitacicept-Data-in-Primary-Sj%C3%B6gren-s-Disease.html

    GLOBENEWSWIRE
    22 Oct 2025
    Share Share
    Vor Bio Presents China Phase 3 Iga Nephropathy Study At ASN
    Vor Bio Presents China Phase 3 Iga Nephropathy Study At ASN

    17 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/17/3168567/0/en/Vor-Bio-Announces-Late-Breaking-Oral-Presentation-of-China-Phase-3-IgA-Nephropathy-Clinical-Study-at-American-Society-of-Nephrology-s-Kidney-Week-2025.html

    GLOBENEWSWIRE
    17 Oct 2025
    Share Share
    Vor Bio Publishes China Phase 3 Telitacicept Study In Lupus
    Vor Bio Publishes China Phase 3 Telitacicept Study In Lupus

    16 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/16/3167846/0/en/Vor-Bio-Announces-Publication-of-China-Phase-3-Study-of-Telitacicept-in-Systemic-Lupus-Erythematosus-in-The-New-England-Journal-of-Medicine.html

    GLOBENEWSWIRE
    16 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search